Gilder Gagnon Howe & CO LLC Arcutis Biotherapeutics, Inc. Transaction History
Gilder Gagnon Howe & CO LLC
- $8.41 Billion
- Q3 2025
A detailed history of Gilder Gagnon Howe & CO LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Gilder Gagnon Howe & CO LLC holds 4,429,108 shares of ARQT stock, worth $111 Million. This represents 0.99% of its overall portfolio holdings.
Number of Shares
4,429,108
Previous 4,155,763
6.58%
Holding current value
$111 Million
Previous $58.3 Million
43.3%
% of portfolio
0.99%
Previous 0.69%
Shares
7 transactions
Others Institutions Holding ARQT
# of Institutions
253Shares Held
127MCall Options Held
404KPut Options Held
133K-
Jennison Associates LLC12.3MShares$306 Million0.14% of portfolio
-
Rubric Capital Management LP New York, NY10.7MShares$269 Million3.33% of portfolio
-
Suvretta Capital Management, LLC New York, NY10.5MShares$262 Million5.93% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA9.87MShares$247 Million7.87% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$216 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $1.5B
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...